• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lite Strategy Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    12/30/25 6:00:41 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LITS alert in real time by email
    8-K
    false000126210400012621042025-12-232025-12-23

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 23, 2025

     

     

    Lite Strategy, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41827

    51-0407811

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    9920 Pacific Heights Blvd.,

    Suite 150

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 858 369-7100

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.00000002 par value

     

    LITS

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    As previously disclosed on Form 8-K by Lite Strategy, Inc. (the Company) with the Securities and Exchange Commission (the SEC) on November 18, 2025, the Board of Directors (the Board) of the Company appointed Justin J. File as Chief Executive Officer, effective as of November 14, 2025, in addition to his current roles of Chief Financial Officer and Secretary. On December 23, 2025, the Company and Mr. File entered into an employment agreement, effective November 14, 2025 (the 2025 File Employment Agreement), commemorating this appointment and replacing Mr. File’s prior amended and restated employment agreement with the Company, dated August 1, 2024, which was previously filed with the SEC as Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed on March 7, 2025. The terms of the 2025 File Employment Agreement with the Company are discussed below in this Current Report on Form 8-K.

    Approval of Amended and Restated Justin J. File Employment Agreement

    The 2025 File Employment Agreement provides for (i) a base salary of $575,000, effective as of October 1, 2025, (ii) a target annual bonus opportunity of 50% base salary, effective for the fiscal year beginning July 1, 2025, (iii) eligibility to participate in the Company’s health, retirement, expense reimbursement, and other benefit plans on terms no less favorable than those provided to other senior executives of the Company, and (iv) eligibility to receive equity awards on similar terms as other senior executives of the Company under the Company’s equity compensation plan. The term of the 2025 File Employment Agreement commences as of November 14, 2025 and continues indefinitely until termination by either Mr. File or the Company, as described below.

    Under the 2025 File Employment Agreement, if Mr. File’s employment is terminated (i) by the Company other than for cause, (ii) by Mr. File for good reason, or (iii) due to Mr. File’s death or disability (in each case, as defined in the 2025 File Employment Agreement), Mr. File will be eligible to receive the following severance benefits (collectively, the Severance Benefits):

    •
    A lump sum payment equal to 12 months of his base salary as in effect at the time of termination.
    •
    Subject to Mr. File’s election of health care continuation coverage, monthly COBRA reimbursements for Mr. File and his eligible dependents until the earliest of (A) the 12-month anniversary of Mr. File’s date of termination, and (B) the date he is no longer eligible to receive COBRA continuation coverage.
    •
    A lump sum payment of a pro-rata target annual bonus for the year of termination.
    •
    Accelerated vesting of the portion of Mr. File’s outstanding stock options equal to the number of options that would have vested if he had continued to be employed by the Company for 12 months following termination.

    Except in the case of Mr. File’s death, the payment of the Severance Benefits will be conditioned upon Mr. File’s execution of an effective release of claims.

    The 2025 File Employment Agreement also provides that if the Company terminates Mr. File’s employment without cause in the three month period prior to a change in control at the request of the other party to the change in control transaction, or if upon or within two years following a change in control, Mr. File’s employment is terminated by the Company without cause or by Mr. File for good reason, then Mr. File’s outstanding stock options will fully vest and become exercisable as of his termination date, provided that he signs an effective release of claims.

    In connection with his entering into the 2025 File Employment Agreement, Mr. File entered into an Employee Proprietary Information and Inventions Agreement (the Proprietary Information Agreement), dated December 23, 2025, which will replace and supersede his prior proprietary information agreement, dated June 9, 2023.

    The foregoing summary of the 2025 File Employment Agreement and the Proprietary Information Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the 2025 File Employment Agreement and the Proprietary Information Agreement. The full text of the 2025 File Employment Agreement is attached as Exhibit 10.1 and the full text of the Proprietary Information Agreement is attached as Exhibit 10.2 to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

    Exhibit Number

    Exhibit Title

    10.1

    Employment Agreement between the Company and Justin J. File, dated December 23, 2025

    10.2

    Employee Proprietary Information and Inventions Agreement between the Company and Justin J. File, dated December 23, 2025

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    LITE STRATEGY, INC.

     

     

     

     

    Date:

    December 30, 2025

    By:

    /s/ Justin J. File

     

     

     

    Justin J. File
    Chief Executive Officer, Chief Financial Officer and Secretary

     


    Get the next $LITS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LITS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LITS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Schornstein Alexander sold $946,137 worth of shares (690,611 units at $1.37), decreasing direct ownership by 16% to 3,674,862 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:15:14 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $97,699 worth of shares (70,000 units at $1.40), increasing direct ownership by 233% to 100,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by CEO, CFO and Secretary File Justin J.

    4/A - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 5:29:57 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Flynn James P bought $97,699 worth of shares (70,000 units at $1.40), increasing direct ownership by 233% to 100,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $22,777 worth of shares (12,100 units at $1.88), increasing direct ownership by 68% to 30,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

    SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate events related to the Company's digital asset treasury strategy as well as its pharmaceutical operations. "Our first quarter was incredibly successful for LITS. We launched our digital treasury strategy, positioning ourselves as the leading public holder of LTC, and updated our corporate profile to reinforce our new focus," Board Member Charlie Lee said. "We recently celebrated Litecoin's 14th anniversary and its unblemished track record of reliability and uptime. LITS provides inv

    11/17/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

    SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today announced its Board of Directors has authorized a program to repurchase shares of the Company's Common Stock, par value $0.00000002 per share (the "Common Stock"), up to an aggregate amount of $25 million. The share repurchase program is effective immediately, and provides for shares to be repurchased in the open market or through negotiated transactions. "Our top priority is to enhance stockholder value," said Board Member Joshua Riezman, U.S. Chief Strategy Officer at GSR, which is advising the Company on its treasury strategy, "and the share repurchase program is one of th

    10/29/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026

    SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS"), the first U.S.-listed public company to adopt Litecoin as its primary reserve asset, joins the digital asset community in celebrating the 14th anniversary of Litecoin (LTC), and its role as the second-longest-running blockchain in crypto and a model of network resilience. "As we celebrate this historic time, we see that Litecoin's 14-year track record of reliability and uptime continues to attract more institutional interest. As institutions look for digital assets with proven durability and sound hard-money principles, Litecoin stands out as a strong choice for both treasury divers

    10/16/25 4:06:43 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Lite Strategy Inc.

    DEFA14A - Lite Strategy, Inc. (0001262104) (Filer)

    12/30/25 4:05:02 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Lite Strategy Inc.

    DEF 14A - Lite Strategy, Inc. (0001262104) (Filer)

    12/30/25 4:00:34 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    12/30/25 6:00:41 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care